Clinical Trials Logo

Osteoporosis, Postmenopausal clinical trials

View clinical trials related to Osteoporosis, Postmenopausal.

Filter by:

NCT ID: NCT00545480 Completed - Clinical trials for Post Menopausal Osteoporosis

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

Start date: July 2006
Phase: Phase 4
Study type: Interventional

This 2 arm study will assess the impact of bone marker feedback, using blood sampling and communication of results at week 5, on persistence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis. The study will also assess safety, quality of life and patient satisfaction. All patients will receive Bonviva 150mg po monthly, and will be randomized into the bio-feedback or no bio-feedback study arms. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00545363 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Adherence to Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP).

Start date: May 2006
Phase: Phase 4
Study type: Interventional

This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using serum CTX and communication of results at 3 months, on adherence to once monthly Bonviva (150mg po) in women with post-menopausal osteoporosis supported by PRP. Patients will be randomized either to receive BMF or no BMF; both groups will be supported by PRP. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00545090 Completed - Clinical trials for Post Menopausal Osteoporosis

ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Start date: August 2006
Phase: Phase 4
Study type: Interventional

This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study. All patients completing 6 months in ML19930 will continue to receive Bonviva (150mg po, monthly) for an additional 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00545051 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Start date: May 2006
Phase: Phase 4
Study type: Interventional

This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

NCT ID: NCT00543218 Completed - Clinical trials for Osteoporosis, Post-Menopausal

PTH Comparison in Post Menopausal Women

Start date: December 2002
Phase: Phase 3
Study type: Interventional

Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.

NCT ID: NCT00543023 Completed - Clinical trials for Osteoporosis, Post-Menopausal

A Study of the Treatment of Postmenopausal Women With Osteoporosis

Start date: June 2003
Phase: Phase 3
Study type: Interventional

To compare the effect of treatment with teriparatide with that of salmon calcitonin in postmenopausal women with osteoporosis.

NCT ID: NCT00542984 Completed - Clinical trials for Osteoporosis, Postmenopausal

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Start date: August 2003
Phase: Phase 3
Study type: Interventional

To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.

NCT ID: NCT00541658 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

NCT ID: NCT00533650 Completed - Clinical trials for Post-Menopausal Osteoporosis

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Start date: December 2000
Phase: Phase 2
Study type: Interventional

A study to asses the safety and efficacy of MK0429 in postmenopausal women with osteoporosis.

NCT ID: NCT00532545 Completed - Clinical trials for Osteoporosis, Post-Menopausal

Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Start date: April 2003
Phase: Phase 4
Study type: Interventional

To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population